![\"Long](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/05\/A18FE572E10C144C41AF97DF1880E31D.jpg\")
<\/p>\n <\/p>\n
LONG ISLAND<\/strong> – Michael, a 48-year-old from Suffolk County, is suing Ozempic’s manufacturer for partial loss of vision.<\/p>\n Losing weight, losing eyesight? <\/p>\n What we know:<\/p>\n Michael, who opted out of sharing his surname, says that the loss of sight began after his endocrinologist recommended he switch from Metformin to Ozempic to manage his type 2 diabetes.\u00a0<\/p>\n Michael told FOX 5 NY’s<\/strong> Jodi Goldberg that he lost 10 pounds, but also some vision in both eyes.\u00a0<\/p>\n “From the bottom right side of my eye\u2026 if I close the left eye, faces get blurry, I can’t read my cell phone.” He claims he had 20\/20 vision before taking Ozempic.<\/p>\n Michael was diagnosed with NAION<\/a> (Non-arteritic Anterior Ischemic Optic Neuropathy), which is essentially a stroke of the eye \u2013 it presents as an acute but painless loss of vision in one eye.<\/p>\n No treatment for NAION currently exists. One of the most recognized risk factors for NAION is diabetes.<\/p>\n However, two recent studies \u2013 one from the JAMA Network<\/a> and the other out of Denmark<\/a> \u2013 suggest there could be a link between the condition and taking semaglutide, which is the active ingredient in Ozempic<\/a>.<\/p>\n Ozempic lawsuit <\/p>\n Jason Goldstein of Parker Waichman LLP<\/a>, a personal injury, mass tort and environmental law firm, has filed a multimillion dollar lawsuit against Novo Nordisk<\/a>, the manufacturer of Ozempic and Wegovy<\/a>, a similar medication.<\/p>\n Goldstein is representing more than 30 clients from 10 states suffering from the same side effect, including Michael.<\/p>\n “This lawsuit is about holding Novo Nordisk responsible for not warning doctors and their patients this condition could develop,” Goldstein said.<\/p>\n Recalled drugs <\/p>\n Dig deeper:<\/p>\n Over the past decade, the U.S. Food and Drug Administration<\/a> (FDA) has recalled over 14,000 drugs<\/a>; rare side effects can be missed during clinical trials and may not be discovered until later on.<\/p>\n Goldberg spoke to Dr. Chetna Bakshi\u00a0about how common reactions to medications like Ozempic could be. Bakshi’s take is that more research is necessary.<\/p>\n “These medications come out, people take them, and it’s not until 10 or 15 years later that we find other complications that weren\u2019t apparent in the initial clinical trials.”<\/p>\n Novo Nordisk’s response <\/p>\n The other side:<\/p>\n A spokesperson for Novo Nordisk gave FOX 5 this statement:\u00a0<\/p>\n “Patient safety is a top priority for Novo Nordisk, and we take all reports about adverse events from use of our medicines very seriously. After a thorough evaluation of studies from the University of Southern Denmark and Novo Nordisk’s internal safety assessment, Novo Nordisk is of the opinion that the benefit-risk profile of semaglutide remains unchanged.”<\/p>\n Goldstein’s response: “It was a drug you were taking, that there were other options on the market, and no one warned you this could happen.”<\/p>\n The Source:<\/b> This article includes reporting from FOX 5 NY’s Jodi Goldberg, as well as two medical studies from the JAMA Network and a Danish-Norwegian cohort.<\/p>\n![\"\"](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/05\/lawyer.jpg\")
<\/p>\n